Thread regarding Schrödinger layoffs

Clinical layoffs highlight leadership incompetence

Schrodinger began laying off the clinical team today. They’re also ending “independent” clinical development, which really closes the door on their entire clinical pipeline - especially since these poor performing assets have failed to attract any partner interest even after years of development. The Chief Medical Officer is also leaving.

These actions highlight the failure of Schrodinger’s executive leadership and board of directors. Their inability to deliver any assets that can succeed in the clinic is a direct reflection their incompetence, inexperience and ineffective leadership. There’s a repeated pattern of poor judgment, weak decision-making, and avoidance of accountability. It’s amazing that, despite this utter abysmal performance, the C-suite and BoD has not been held accountable. It’s time to clean house and find competent replacements that can deliver results.


by
| 401 views | | 1 reply (November 10) | Reply
Post ID: @OP+1k9bsrjcm

1 reply

It feels like the company is headed for a complete collapse. The layoffs five months ago, continuing with this latest round, just confirm the trend. The real issue is the failure of our core scientific platform—after all this time, we still don’t have any clinically viable molecules. With clinical programs discontinued, no partnerships, increasing AI competition, and lack of innovation, it’s hard to see how Schrodinger survives much longer.

by
| | Reply
Post ID: @xb+1k9bsrjcm

Post a reply

: